1K Ghost Deal	**$18.02M** Unrecognized Revenue	

Total Pipeline, Dated Pipeline and Validated Revenue

100%

Total Pipeline	$2.15bn
Dated Pipeline	$2.04bn
Validated Revenue	$0.34bn

16%

| Sales_Rep_ID	Opportunity_ID	Deal_Size	Activity_Count
1	253	$100,226	5
1	280	$9,421	12
1	400	$86,233	2
1	586	$494,867	3
1	612	$429,948	5
1	630	$396,759	9
1	960	$231,081	10
1	1001	$300,450	6
1	1055	$320,209	7
1	1089	$352,157	2
1	1185	$260,001	4
1	1768	$481,834	11
1	1791	$45,595	16
1	2589	$117,726	6

Insights

1: Pipeline Integrity & 'Ghost' Revenue
- **What was seen:** 1,000 opportunities lack closing dates, resulting in **$18.02M** in unrecognized revenue.
- **Insight:** This data gap makes the pipeline unforecastable and distorts the **Validated Revenue** baseline of **$0.34bn**.
- **Action: Enforce Mandatory CRM Governance**: Implement hard-stop validation rules at the CRM entry point to ensure every 'Won' deal has a timestamp, converting 'Ghost Revenue' into bankable cash.

2: Strategic Execution Deficit
- **What was seen:** The current **Win Rate is 20.94%** against a **30.00% strategic target**.
- **Insight:** The organization is operating at a **30% execution deficit**, indicating that sales tactics are

Sales Effectiveness & Discount Optimization

Win Rate % and Target %

30.00%

20.94%

0.00%   100.00%

20.00%
Avg Discount %

Revenue and Total Target Revenue by YearMonth

● Validated Revenue ● Total Target Revenue

Revenue Performance by Region, Industry and Campaign

Revenue by Industry

Revenue by Region

Revenue by Campaign_Name

- harness scalable web services
- strategize frictionless metrics
- evolve dot-com architectu...
- transform global info-me...
- productize e-business architectures
- enable world-class fu...
- leverage one-to-one ...
- e-enable visionary action-items
- syndicate bricks-and-clicks ...
- cultivate cutting-edge par...
- optimize distributed ban...
- scale collaborative content
- envisioneer distributed functionalities
- re-intermediate bleed...
- aggregate cross-plat...

Sales Velocity & Pipeline Efficiency

103.18
Avg Sales Cycle

$446.27M
Stalled Revenue

Avg Sales Cycle and Total Pipeline by Opportunity_ID and Region

Region ● Americas ● APAC ● EMEA

Avg Sales Cycle by Industry

Pharma

Industrial

Environmental

Life Sciences

Diagnostics

Revenue Composition and Concentration Analysis

## Validated Revenue, Pareto % and Pareto Threshold by Account_Name

● Validated Revenue ● Pareto % ● Pareto Threshold

Key Drivers of Revenue

Key influencers   Top segments

What influences Validated Revenue to [Increase ▼] ?

When...   ....the average of Validated
                           Revenue increases by

| Account_Size is Enterprise ━━━━━━━━━━━━━━━━━━━━━▶ ($188.3K)

← Validated Revenue is more likely to increase when Account_Size is Enterprise than otherwise (on average).

$200K

$150K

$100K

Average (excluding selected): $88,204.76
‑‑

$50K

$0K

        Enterprise   Mid-Market   SMB

Account_Size

(Average of Validated Revenue — y-axis)

☐ Only show values that are influencers

Revenue Recovery & Pipeline Optimization Simulation

Win Rate Target

30%

⚪

$2.15bn	**$195.27M**	**$539.36M**	**56.75%**
Total Pipeline	Projected Revenue Unlock	Revenue after Unlock	Revenue Growth %

Insights

1. Operational Friction (The $446M Bottleneck)
- **What was seen:** **$446.27M** is currently classified as **Stalled Revenue**.
- **Insight:** Nearly half a billion dollars is 'rotting' in the pipeline because deals are exceeding the **103.18-day average success cycle.**
- **Action: Execute a velocity increase mandatory timeline for the sales reps**: The leadership team must mandate a 60-day 'Close-or-Kill' review for all stalled accounts over **$0.2M** to reclaim sales capacity and clear pipeline deadwood.

2: Segment Alignment & Sector Lag
- **What was seen: Pharma and Industrial** segments show significantly longer sales cycles than core Diagnostics.
- **Insight:** Strategic expansion into high-margin sectors is being throttled by a **100+ day friction barrier** that doesn't exist in legacy markets.
- **Action: Standardize Global Workflows**: Adopt the high-velocity conversion model identified in the **APAC region** and apply it to the Pharma sector globally to reduce cycle times by the required efficiency targets.

3: The $195M Revenue Opportunity
- **What was seen**: The current organizational **Win Rate is 20.94%**, creating a **9.06% performance gap** against the **30.00% strategic target**.
- **Insight**: This execution gap represents a failure to capture **$195.27M** in available pipeline revenue, which effectively suppresses our current realized growth by **56.75%**.
- **Action**: **Launch a recovery mechanism that** prioritizes a competitive audit of lost deals in our top-tier segments to identify why we are failing to convert the nearly **$200M** in "Found Revenue".

4. Strategic Revenue Concentration (Pareto Audit)
- **What was seen:** A Pareto analysis of the **$0.34bn Validated Revenue** reveals that **80% of company's income** is generated by approximately **21% of total account base**. Top accounts like **Boyd-Hart** and **Colton PLC** are the primary drivers of our current growth baseline.
- **Insight:** These 20% of accounts represent the highest **ROI for commercial efforts**; any efficiency gains in their sales cycle deliver an exponential impact compared to the remaining 80% of the pipeline.